U.S. FDA approves nasal spray to treat children's migraines
A new treatment for migraine headaches is now available for children in the U.S. (© Pressmaster/shutterstock.com)
The U.S. Food and Drug Administration approved the drug ZOMIG Nasal Spray to treat migraine headaches in pediatric patients between the ages of 12 and 17, parent company Impax Specialty Pharma announced Tuesday.
Intended for acute treatment of migraines, ZOMIG is thought to be the first nasal-delivered prescription treatment for pediatric patients.
ZOMIG can be used for migraines with aura -- those accompanied by symptoms before the headache even begins -- and migraines without aura.
In a given year, as much as 6.3 per cent of US children between the ages of 12 and 19 will suffer a migraine, according to The American Migraine Prevalence and Prevention (AMPP).